SOMERSET, N.J. – Aug 24, 2020 — Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene therapy manufacturing facility located in Harmans, Maryland.
{iframe}https://biologics.catalent.com/catalent-news/catalent-signs-agreement-with-astrazeneca-to-expand-manufacturing-support-for-covid-19-vaccine-azd1222/?source=7013b000001N8Jp&utm_source=LinkedIn&utm_medium=Social-Media-Org&utm_campaign=FY21-CGT-Social-ORG-LNKD-AZ-Covid19-Expansion-PR-Announcement-Post1-Aug20&utm_content=AZ-Covid-Expansion-PR-Announcement{/iframe}